Taking next-gen mAbs to new heights will lead modality innovation

Improving on validated technologies trumps forging new ones when it comes to expectations for new modalities in the next few years. Despite the proliferation of modalities, from gene therapies and RNAs to different kinds of cell therapy, it is the next-gen formats of the antibody workhorse that will drive the greatest progress into the second half of this decade, according to investors and executives surveyed by BioCentury.

Though small molecules and traditional mAbs will remain core to drug development, the engine of innovation is clearly in high gear for creation and improvement of new modality therapeutics...